Pioneering affordable virotherapy from India, for the world.
Founded in Bangalore, Neovira Therapeutics is among the first companies in India focused on oncolytic virotherapy innovation. Our viruses are engineered to selectively target and destroy cancer cells, transforming one of medicine’s greatest challenges into a new frontier of treatment.
Market Opportunity
Cancer immunotherapy is growing rapidly in India
Valued at USD 3.3 billion in 2023, the sector is expected to nearly triple by 2030, powered by demand for innovative treatments. Yet within this evolving market, oncolytic virotherapy remains in its infancy in India, with very few efforts advancing toward clinical translation.
Access to advanced therapies in India remains limited.
Despite growing demand, next-generation treatments such as virotherapies are still out of reach for most patients due to high overall treatment costs and the absence of locally manufactured options. This gap highlights a significant affordability and availability challenge in the Indian oncology ecosystem.
Neovira Therapeutics is uniquely positioned to change this.
By building local manufacturing capacity and advancing affordable, home- grown virotherapies, we aim to make advanced cancer treatments accessible to Indian patients, while unlocking export opportunities to Asia and the Middle East.